Neuromodulation Market Growth Outlook Through 2024-2033

Overview and Scope
Neuromodulation is the modification of nerve activity (or modulation) by delivering electrical or pharmacological substances directly to a specific location. It is a reversible procedure performed to relieve pain.

Sizing and Forecast
The neuromodulation market size has grown rapidly in recent years. It will grow from $6.43 billion in 2023 to $7.14 billion in 2024 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to rising prevalence of chronic disorders, clinical evidence and research, patient demand for non-invasive therapies, government initiatives and funding, expansion of indications, collaborations and partnerships.

The neuromodulation market size is expected to see rapid growth in the next few years. It will grow to $10.64 billion in 2028 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to miniaturization of devices, focus on neurological disorders in aging population, expanded applications in psychiatry, patient-centric approaches, global expansion of healthcare access. Major trends in the forecast period include integration of artificial intelligence (ai), advancements in technology, non-invasive neuromodulation techniques, closed-loop neuromodulation systems, expansion of indications, wireless and wearable neuromodulation devices.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/neuromodulation-global-market-report

Segmentation & Regional Insights
The neuromodulation market covered in this report is segmented –

1) By Technology: Internal Neuromodulation, External Neuromodulation (Non-invasive)
2) By Biomaterial: Polymeric Biomaterial, Metallic Biomaterial, Ceramic Biomaterial
3) By Application: Chronic Pain, Urinary And Fecal Incontinence, Migraine, Failed Back Syndrome, Parkinson Disease, Epilepsy, Tremor, Depression, Other Applications
4) By End-User: Hospitals, Clinics, Home Healthcare

North America was the largest region in the neuromodulation market in 2023. The regions covered in the neuromodulation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10142&type=smp

Major Driver Impacting Market Growth
The growing prevalence of neurological disorders is expected to propel the growth of the neuromodulation market going forward. Neurological disorders are technically defined as problems that affect the brain as well as the nerves located throughout the human body and the spinal cord. Neuromodulation offers the ability to cure and modulate a wide range of neurological disorders and diseases, such as Parkinson’s and Alzheimer’s diseases. For example, in April 2022, according to the European Brain Council, a Belgium-based coordinating international health organization, there were over 600 neurological diseases and nearly 300 psychiatric conditions noted. Worldwide, there were 50 million people living with Alzheimer’s and other dementias. Epilepsy is common disorder that affected 65 million people around the world. In Europe, 10.5 million people had dementia, which is expected to increase to 18.7 million in 2050. Thus, the growing prevalence of neurological disorders is driving the growth of the neuromodulation market.

Key Industry Players
Major companies operating in the neuromodulation market report are Abbott Laboratories, Soterix Medical Inc., Boston Scientific Corporation, Medtronic plc, Synapse Biomedical Inc., Nevro Corp, Neuropace Inc., LivaNova PLC, Neurosigma Inc., Neuronetics Inc., Bioness Inc., Aleva Neurotherapeutics S.A., Integer Holdings Corporation, ReShape Lifesciences Inc., Inspire Medical Systems Inc., Bioventus LLC, Saluda Medical Pty Ltd, Otolith Labs Inc., Machine Medicine Inc., Inbrain Neuroelectronics SAS, Pixium Vision SA, Neuromod Devices Limited, Cognito Therapeutics Inc., PathMaker Neurosystems Inc., Dignify Therapeutics Inc., Neuronoff ApS, Neuros Medical Inc., Fisher & Paykel Healthcare Corporation Limited, Koninklijke Philips N.V., Magic Leap Inc., Omron Corporation

The neuromodulation market report table of contents includes:

1. Executive Summary
2. Neuromodulation Market Characteristics
3. Neuromodulation Market Trends And Strategies
4. Neuromodulation Market – Macro Economic Scenario
5. Global Neuromodulation Market Size and Growth
.
.
.
31. Global Neuromodulation Market Competitive Benchmarking
32. Global Neuromodulation Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Neuromodulation Market
34. Neuromodulation Market Future Outlook and Potential Analysis
35. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model